TSLC1 gene silencing in cervical cancer cell lines and cervical neoplasia.

BACKGROUND Cervical carcinogenesis is initiated by infection with high-risk (i.e., carcinogenic) human papillomavirus (HPV) types. The subsequent progression from premalignant cervical intraepithelial neoplasia (CIN) to invasive cancer is driven by both genetic and epigenetic processes. We assessed the role of the gene encoding the adhesion molecule tumor suppressor in lung cancer 1 (TSLC1) in this progression. METHODS We analyzed TSLC1 gene expression by real-time quantitative reverse transcription-polymerase chain reaction, promoter methylation by sodium bisulfite genomic DNA sequencing, and allelic loss by microsatellite analysis in primary keratinocytes, in four non-tumorigenic HPV-immortalized human keratinocyte cell lines, and in 11 human cervical cancer cell lines that were positive for a high-risk HPV DNA type and in normal cervical epithelial cells. We transfected cervical cancer SiHa cells that did not express TSLC1 mRNA with an expression vector containing the TSLC1 complementary DNA (cDNA) or an empty vector and analyzed transfectants for anchorage-independent growth and tumorigenicity in nude mice. We also examined TSLC1 promoter methylation in premalignant cervical lesions and in cervical carcinomas and smears. All statistical tests were two-sided. RESULTS TSLC1 mRNA was strongly reduced, relative to levels in primary keratinocytes, or absent in 10 (91%) of 11 cervical carcinoma cell lines but in none (0%) of the four HPV-immortalized cell lines (difference = 91%, 95% confidence interval [CI] = 74% to 100%; P =.004). The TSLC1 promoter was hypermethylated, relative to normal foreskin and cervical epithelial cells, in nine (82%) of the 11 cervical carcinoma cell lines but in none (0%) of the four HPV-immortalized cell lines (difference = 82%, 95 CI = 59% to 100%; P =.01). Seven (88%, 95% CI = 47% to 100%) of the eight SiHa/TSLC1 transfectants displayed a marked reduction in anchorage-independent growth (i.e., 0-100 colonies per 5000 cells) compared with none of the four (0%, 95% CI = 0% to 60%) SiHa transfectants bearing the empty vector (i.e., SiHa/hygro transfectants; difference = 88%, 95% CI = 65% to 100%; P =.01) or untransfected SiHa cells. All seven mice (100%, 95% CI = 59% to 100%) injected with untransfected SiHa cells or SiHa/hygro transfectants displayed tumors of at least 50 mm(3) by 2-6 weeks after injection compared with none of eight mice (0%, 95% CI = 0% to 37%) injected with the SiHa/TSLC1 transfectants (difference = 100%, 95% CI = 68% to 100%; P<.001). We detected TSLC1 promoter hypermethylation in seven (35%, 95% CI = 15% to 59%) of 20 high-grade CIN lesions (i.e., CIN II and III) and in 30 (58%, 95% CI = 43% to 71%) of 52 cervical squamous cell carcinomas compared with none (0%, 95% CI = 0% to 34%) of nine normal cervical epithelial biopsy samples and none (0%, 95% CI = 0% to 22%) of 12 CIN I lesions (P<.001 for cervical squamous cell cancer versus normal epithelial biopsy samples plus CIN I lesions). CONCLUSIONS TSLC1 gene silencing via promoter hypermethylation is a frequent event in the progression from high-risk HPV-containing, high-grade CIN lesions to invasive cervical cancer.

[1]  R. Richart.  Causes and management of cervical intraepithelial neoplasia , 1987, Cancer.

[2]  B. C. Misra,et al.  Loss of heterozygosity for alleles on chromosome II in cervical carcinoma. , 1991, American journal of human genetics.

[3]  P. Stern,et al.  Multiple mechanisms underlie HLA dysregulation in cervical cancer. , 2000, Tissue antigens.

[4]  D. Gerhard,et al.  Loss of heterozygosity at 11q23.3 in vasculoinvasive and metastatic squamous cell carcinoma of the cervix. , 2001, Human pathology.

[5]  C. Meijer,et al.  Telomerase activity in high‐grade cervical lesions is associated with allelic imbalance at 6Q14–22 , 2003, International journal of cancer.

[6]  J. Lahti-Domenici,et al.  Analysis of 11q21–24 loss of heterozygosity candidate target genes in breast cancer: Indications of TSLC1 promoter hypermethylation , 2002, Genes, chromosomes & cancer.

[7]  C. Herrington,et al.  Loss of heterozygosity occurs at the D11S29 locus on chromosome 11q23 in invasive cervical carcinoma. , 1995, British Journal of Cancer.

[8]  H. Fukuhara,et al.  The Tumor Suppressor Protein TSLC1 Is Involved in Cell-Cell Adhesion* , 2002, The Journal of Biological Chemistry.

[9]  J. Peto,et al.  Human papillomavirus is a necessary cause of invasive cervical cancer worldwide , 1999, The Journal of pathology.

[10]  G. Evans,et al.  Deletion and translocation of chromosome 11q13 sequences in cervical carcinoma cell lines. , 1995, American journal of human genetics.

[11]  C. Meijer,et al.  Transition of human papillomavirus type 16 and 18 transfected human foreskin keratinocytes towards immortality: activation of telomerase and allele losses at 3p, 10p, 11q and/or 18q. , 1996, Oncogene.

[12]  B. Roe,et al.  Localization of deletion to a 300 Kb interval of chromosome 11q13 in cervical cancer , 2002, Oncogene.

[13]  P. Snijders,et al.  POBASCAM, a population‐based randomized controlled trial for implementation of high‐risk HPV testing in cervical screening: Design, methods and baseline data of 44,102 women , 2004, International journal of cancer.

[14]  V. Defendi,et al.  Genetic analysis of in vitro progression of human papillomavirus-transfected human cervical cells. , 1993, Cancer research.

[15]  C. Meijer,et al.  A general primer GP5+/GP6(+)-mediated PCR-enzyme immunoassay method for rapid detection of 14 high-risk and 6 low-risk human papillomavirus genotypes in cervical scrapings , 1997, Journal of clinical microbiology.

[16]  B. Westerman,et al.  Quantitative reverse transcription-polymerase chain reaction measurement of HASH1 (ASCL1), a marker for small cell lung carcinomas with neuroendocrine features. , 2002, Clinical cancer research : an official journal of the American Association for Cancer Research.

[17]  H. Hausen.  Papillomaviruses and cancer: from basic studies to clinical application , 2002, Nature Reviews Cancer.

[18]  C. Meijer,et al.  Telomerase activity exclusively in cervical carcinomas and a subset of cervical intraepithelial neoplasia grade III lesions: strong association with elevated messenger RNA levels of its catalytic subunit and high-risk human papillomavirus DNA. , 1998, Cancer research.

[19]  M. Oshimura,et al.  Normal human chromosome 11 suppresses tumorigenicity of human cervical tumor cell line SiHa , 1989, Molecular carcinogenesis.

[20]  S. Nishizuka,et al.  Hypermethylation of the TSLC1 Gene Promoter in Primary Gastric Cancers and Gastric Cancer Cell Lines , 2002, Japanese journal of cancer research : Gann.

[21]  V. Defendi,et al.  Evolution of in vitro transformation and tumorigenesis of HPV16 and HPV18 immortalized primary cervical epithelial cells. , 1991, The American journal of pathology.

[22]  E. Stanbridge,et al.  Evidence for a putative senescence gene locus within the chromosomal region 10p14-p15. , 2001, Cancer research.

[23]  C. Meijer,et al.  Viral E6-E7 Transcription in the Basal Layer of Organotypic Cultures without Apparent p21cip1 Protein Precedes Immortalization of Human Papillomavirus Type 16- and 18-Transfected Human Keratinocytes , 1998, Journal of Virology.

[24]  L. E. McDonald,et al.  A genomic sequencing protocol that yields a positive display of 5-methylcytosine residues in individual DNA strands. , 1992, Proceedings of the National Academy of Sciences of the United States of America.

[25]  G. Peters,et al.  Schedule-dependent therapeutic efficacy of the combination of gemcitabine and cisplatin in head and neck cancer xenografts. , 1995, European journal of cancer.

[26]  Bill Broyles.  Notes , 1907, The Classical Review.

[27]  Paola Pisani,et al.  Estimates of the world‐wide prevalence of cancer for 25 sites in the adult population , 2002, International journal of cancer.

[28]  B. Achinstein,et al.  Journal of the National Cancer Institute, Vol. 29, 1962: Action of bacterial polysaccharide on tumors. II. Damage of sarcoma 37 by serum of mice treated with Serratia marcescens polysaccharide, and induced tolerance. , 2009, Nutrition reviews.

[29]  H. Fukuhara,et al.  TSLC1 is a tumor-suppressor gene in human non-small-cell lung cancer , 2001, Nature Genetics.

[30]  K. Münger,et al.  Functions of human papillomavirus proteins. , 1994, Current topics in microbiology and immunology.

[31]  R. Hruban,et al.  Aberrant Methylation of the 5' CpG Island of TSLC1 Is Common in Pancreatic Ductal Adenocarcinoma and Is First Manifest in High-Grade PanINs , 2002, Cancer biology & therapy.

[32]  Mark Sherman,et al.  The 2001 Bethesda System: terminology for reporting results of cervical cytology. , 2002, JAMA.

[33]  F. X. Bosch,et al.  Epidemiologic classification of human papillomavirus types associated with cervical cancer. , 2003, The New England journal of medicine.

[34]  C. Meijer,et al.  HPV presence precedes abnormal cytology in women developing cervical cancer and signals false negative smears , 2001, British Journal of Cancer.

[35]  G. Evans,et al.  Identification of a 6-cM minimal deletion at 11q23.1-23.2 and exclusion of PPP2R1B gene as a deletion target in cervical cancer. , 2000, Cancer research.

[36]  H. Fukuhara,et al.  Promoter Methylation of TSLC1 and Tumor Suppression by Its Gene Product in Human Prostate Cancer , 2002, Japanese journal of cancer research : Gann.

[37]  J. McDougall,et al.  Progression of human papillomavirus type 18-immortalized human keratinocytes to a malignant phenotype. , 1991, Proceedings of the National Academy of Sciences of the United States of America.

[38]  P. Green,et al.  Identification of p53 gene mutations in bladder cancers and urine samples. , 1991, Science.

[39]  G. Hampton,et al.  Loss of heterozygosity in cervical carcinoma: subchromosomal localization of a putative tumor-suppressor gene to chromosome 11q22-q24. , 1994, Proceedings of the National Academy of Sciences of the United States of America.

[40]  Sudhir Srivastava,et al.  Markers for early detection of cancer: Statistical guidelines for nested case-control studies , 2002, BMC medical research methodology.

[41]  H. Hollema,et al.  Telomerase in (pre)neoplastic cervical disease. , 2000, Human pathology.

[42]  C. Meijer,et al.  Telomerase suppression by chromosome 6 in a human papillomavirus type 16-immortalized keratinocyte cell line and in a cervical cancer cell line. , 2001, Journal of the National Cancer Institute.

[43]  E. Stanbridge,et al.  Microcell‐mediated transfer of chromosome 4 into HeLa cells suppresses telomerase activity , 2001, Genes, chromosomes & cancer.

[44]  E. Stanbridge,et al.  Introduction of human chromosome 11 via microcell transfer controls tumorigenic expression of HeLa cells. , 1986, The EMBO journal.